<DOC>
	<DOCNO>NCT01154010</DOCNO>
	<brief_summary>The purpose study determine medical device ( ActiPatch ) emit low frequency pulse electromagnetic field ( PEMF ) benefit patient anterior uveitis . Anterior uveitis ( aka iritis ) inflammatory disease involve front segment eye . This common cause painful red eye , ActiPatch show effective treat tissue inflammation . The conventional treatment iritis typically involve frequent administration topical steroid inherent risk ( development cataract and/or glaucoma ) . The purpose study determine ActiPatch therapy use shorten length time and/or quantity steroid administer .</brief_summary>
	<brief_title>PEMF : Adjunct Therapy Anterior Uveitis</brief_title>
	<detailed_description>Iritis inflammatory disease focus anterior chamber eye . The inflammation inside eye lead number condition ultimately effect vision . These include glaucoma , posterior synechiae , cystoid macular edema , cataract . The standard treatment disease drug therapy center around administration corticosteroid . These administered form eye drop , necessary periocular/intraocular injection , or/and systemic oral/IV administration . Unfortunately , treatment corticosteroid similarly induce severe side effect include glaucoma cataract formation . ActiPatch medical device emits low frequency pulse electromagnetic field . This device show reduce inflammation pain number condition , eg blepharoplasty ( eyelid surgery ) . ActiPatch FDA approve use blepharoplasty reduce swell , inflammation pain . The treatment invasive , require additional medication , side effect ActiPatch PEMF device report . The potential benefit treat uveitis ActiPatch potential reduce time and/or amount steroid administration . This would benefit patient reduce risk unwanted side effect corticosteroid treatment . The benefit society would improve treatment anterior uveitis .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Iritis</mesh_term>
	<criteria>Human subject clinically diagnose anterior uveitis ( iritis ) otherwise good health recruit study . The age requirement minimum 18 yr . We recruit 24 patient study . Subjects include clinically diagnose anterior uveitis ( noninfectious ) . Eligibility determine treat Ophthalmologist ( principal investigator ) inclusion study . Vulnerable subject , define Institutional Review Board ( IRB ) , recruit participation ( This include individual 18 , pregnant woman , prisoner , fetus , patient mentally physically unable provide write informed consent ) . Other group exclude include : patient pacemaker patient ferromagnetic metal implant since device may effect pulsed electromagnetic field .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PEMF</keyword>
	<keyword>iritis</keyword>
	<keyword>anterior uveitis</keyword>
</DOC>